BONA [Bona Film] SC 13G/A: (Original Filing)
[SCHEDULE 13G CUSIP No. 09777B107 Page 2 of 12 Pages (1) Names of reporting persons SEQUOIA CAPITAL CHINA I, L.P. (SCC I) I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 20-3514012 (2)]
HMIN [Homeinns Hotel] SC 13G: (Original Filing)
[Page CUSIP No. 43713W107 1. Names of Reporting Persons: 2. Check the Appropriate Box if a Member of a (See Instructions): Joint filing 3. SEC Use Only 4. Citizenship or Place of Organization: Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 0 6. Shared Voting Power:]
TAOM [Taomee] SC 13G: Roc Yunpeng Cheng Charming China Limited EX-99.1 2
[Roc Yunpeng Cheng Charming China Limited EX-99.1 2 d294006dex991.htm JOINT FILING AGREEMENT] [1 NAME OF REPORTING PERSON Roc Yunpeng Cheng 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* ¨ ¨ (a)]
BONA [Bona Film] SC 13G/A: SCHEDULE 13G CUSIP No. 09777B107 Page 2 of
[SCHEDULE 13G CUSIP No. 09777B107 Page 2 of 12 Pages (1) Names of reporting persons SEQUOIA CAPITAL CHINA I, L.P. (SCC I) I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) 20-3514012 (2)]
HMIN [Homeinns Hotel] SC 13G: Page CUSIP No. 43713W107 1. Names of Reporting
[Page CUSIP No. 43713W107 1. Names of Reporting Persons: 2. Check the Appropriate Box if a Member of a (See Instructions): Joint filing 3. SEC Use Only 4. Citizenship or Place of Organization: Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 0 6. Shared Voting Power:]
TAOM [Taomee] SC 13G: (Original Filing)
[Crow Zhen Wei Universys Holdings Ltd. EX-99.1 2 d294009dex991.htm JOINT FILING AGREEMENT] [1 NAME OF REPORTING PERSON Crow Zhen Wei 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* ¨ ¨ (a) 3]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement Press Release: Sinovac Biotech Co., Ltd. – Tue, Jan 24, 2012 4:05 PM EST BEIJING, Jan. 24, 2012 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA - News), a leading provider of vaccines in China, today announced that it received a letter dated January 18, 2012 from The Nasdaq Stock Market. Based] [Sinovac Commences the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease Press Release: Sinovac Biotech Ltd. – Tue, Jan 10, 2012 8:00 AM EST BEIJING , Jan. 10, 2012 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA - News), a leading provider of biopharmaceutical products in China , announced today that the phase III clinical] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F ¨ SINOVAC BIOTECH LTD. 6-K 1 v301323_6k.htm FORM 6-K]
HTHT [China Lodging,] CORRESP: (Original Filing)
[February6, 2012 VIA EDGAR STYLE="font-family:Times New Roman" SIZE="2"> Division ofrporation Finance 100 F Street, N.E. Mail Stop 3010 Attention: Kevin Woody, Branch Chief Howard Efron, Senior Staff Accountant Re: China Lodging, Limited Form 20-F for the year ended December31, 2010 filed on April7, 2011 (File No.1-34656) Dear Mr.Woody and Mr.Efron,]
TAOM [Taomee] SC 13G: Crow Zhen Wei Universys Holdings Ltd. EX-99.1 2
[Crow Zhen Wei Universys Holdings Ltd. EX-99.1 2 d294009dex991.htm JOINT FILING AGREEMENT] [1 NAME OF REPORTING PERSON Crow Zhen Wei 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* ¨ ¨ (a) 3]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee
[Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement Press Release: Sinovac Biotech Co., Ltd. – Tue, Jan 24, 2012 4:05 PM EST BEIJING, Jan. 24, 2012 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA - News), a leading provider of vaccines in China, today announced that it received a letter dated January 18, 2012 from The Nasdaq Stock Market. Based] [Sinovac Commences the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease Press Release: Sinovac Biotech Ltd. – Tue, Jan 10, 2012 8:00 AM EST BEIJING , Jan. 10, 2012 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA - News), a leading provider of biopharmaceutical products in China , announced today that the phase III clinical] [SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F ¨ SINOVAC BIOTECH LTD. 6-K 1 v301323_6k.htm FORM 6-K]
